THERAPY DOSSIER · th-6087039d12f0

carbamylated erythropoietin

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 3

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01016366 ↗PHASE2completed

Study of Lu AA24493 in Patients With Friedreich's Ataxia to Evaluate Safety and Tolerability and to Explore Efficacy

Friedreich's Ataxia

Enrolment: 36 · Results not recorded

NCT00756249 ↗PHASE1completed

Single-dose, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Lu AA24493 (CEPO) in Acute Ischemic Stroke

Acute Ischemic Stroke

Enrolment: 16 · Results not recorded

NCT00870844 ↗PHASE1completed

Multiple-dose, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Lu AA24493 (CEPO) in Patients With Acute Ischemic Stroke

Acute Ischemic Stroke

Enrolment: 24 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21552121 ↗2011Reported benefit

Reduced brain edema and functional deficits after treatment of diffuse traumatic brain injury by carbamylated erythropoietin derivative.

RatTBIWeight-drop / impact-accelerationWistarMalen = 8-10 rats per groupintravenous50 microg/kg30 min after injury

Model: impact-acceleration diffuse TBI

Carbamylated erythropoietin reduced brain oedema up to 6 h post-injury and improved neurological recovery after diffuse TBI.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…